At a glance
- Originator Zambon Group SpA
- Class Anti-ischaemics; Antihypertensives; Ischaemic heart disorder therapies
- Mechanism of Action Beta adrenergic receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Ischaemic heart disorders
Most Recent Events
- 11 Jun 1999 Discontinued-Preclinical for Hypertension in Italy (PO)
- 11 Jun 1999 Discontinued-Preclinical for Ischaemic heart disorders in Italy (PO)
- 03 Sep 1998 No-Development-Reported for Hypertension in Italy (PO)